{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:54:35Z","timestamp":1788346475323,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Leukapheresis is used for the mechanical removal of leukaemic cells in hyperleukocytosis. However, the effectiveness of leukapheresis remains unclear due to selection and confounding factors in the cohorts. We compared the effectiveness of leukapheresis among the subgroups according to either the 2016 World Health Organization classification or the number of cytogenetic abnormalities with a retrospective, single-centre study from January 2009 to December 2018. Acute myeloid leukaemia (AML, n\u2009=\u2009212) and acute lymphoblastic leukaemia (ALL, n\u2009=\u200997) were included. The 30-day survival rates (95% confidence interval, 95% CI) for AML and ALL were 86.3% (81.6\u201390.9%) and 94.8% (90.3\u201399.2%), respectively. For AML, \u2018primary AML with myelodysplasia-related changes\u2019 and \u2018AML with biallelic mutation of\n                    <jats:italic>CEBPA<\/jats:italic>\n                    \u2019 showed better 30-day survival outcomes (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.026) than the other subgroups. A higher platelet count after leukapheresis was associated with better 30-day survival in AML patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.029). A decrease in blast percentage count after leukapheresis was associated with better 30-day survival in ALL patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.034). Our study suggested that prophylactic platelet transfusion to raise the platelet count to 50\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L or greater might improve clinical outcome in AML patients undergoing leukapheresis.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-85918-8","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T09:05:27Z","timestamp":1616144727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The factors influencing clinical outcomes after leukapheresis in acute leukaemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Howon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nack-Gyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Bo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeeun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Wook","family":"Jekarl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyojin","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungshin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"85918_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428190009053534","volume":"39","author":"P Porcu","year":"2000","unstructured":"Porcu, P. et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk. Lymphoma 39, 1\u201318. https:\/\/doi.org\/10.3109\/10428190009053534 (2000).","journal-title":"Leuk. Lymphoma"},{"key":"85918_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","volume":"26","author":"C Ganzel","year":"2012","unstructured":"Ganzel, C., Becker, J., Mintz, P. D., Lazarus, H. M. & Rowe, J. M. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 26, 117\u2013122. https:\/\/doi.org\/10.1016\/j.blre.2012.01.003 (2012).","journal-title":"Blood Rev."},{"key":"85918_CR3","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/asheducation-2014.1.457","volume":"457\u2013460","author":"N Aqui","year":"2014","unstructured":"Aqui, N. & O\u2019Doherty, U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematology 457\u2013460, 2014. https:\/\/doi.org\/10.1182\/asheducation-2014.1.457 (2014).","journal-title":"Hematology"},{"key":"85918_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/pbc.25855","volume":"63","author":"U Creutzig","year":"2016","unstructured":"Creutzig, U. et al. Exchange transfusion and leukapheresis in pediatric patients with AML with high risk of early death by bleeding and leukostasis. Pediatr. Blood Cancer 63, 640\u2013645. https:\/\/doi.org\/10.1002\/pbc.25855 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"85918_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/10428190600572673","volume":"47","author":"MJ Greenwood","year":"2006","unstructured":"Greenwood, M. J. et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk. Lymphoma 47, 1245\u20131252. https:\/\/doi.org\/10.1080\/10428190600572673 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"85918_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bjh.13146","volume":"168","author":"KHM Kuo","year":"2015","unstructured":"Kuo, K. H. M. et al. A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. Br. J. Haematol. 168, 384\u2013394. https:\/\/doi.org\/10.1111\/bjh.13146 (2015).","journal-title":"Br. J. Haematol."},{"key":"85918_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.transci.2015.03.015","volume":"53","author":"I Berber","year":"2015","unstructured":"Berber, I. et al. Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: a single center experience. Transfus. Apher. Sci. 53, 185\u2013190. https:\/\/doi.org\/10.1016\/j.transci.2015.03.015 (2015).","journal-title":"Transfus. Apher. Sci."},{"key":"85918_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1172\/JCI107191","volume":"52","author":"MA Lichtman","year":"1973","unstructured":"Lichtman, M. A. Rheology of leukocytes, leukocyte suspensions, and blood in leukemia. Possible relationship to clinical manifestations. J. Clin. Investig. 52, 350\u2013358. https:\/\/doi.org\/10.1172\/JCI107191 (1973).","journal-title":"J. Clin. Investig."},{"key":"85918_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood.V60.2.279.279","volume":"60","author":"MA Lichtman","year":"1982","unstructured":"Lichtman, M. A. & Rowe, J. M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 60, 279\u2013283. https:\/\/doi.org\/10.1182\/blood.V60.2.279.279 (1982).","journal-title":"Blood"},{"key":"85918_CR10","first-page":"1037","volume":"5","author":"BL Powell","year":"1991","unstructured":"Powell, B. L. et al. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia 5, 1037\u20131042 (1991).","journal-title":"Leukemia"},{"key":"85918_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s002770000162","volume":"79","author":"A Thi\u00e9baut","year":"2000","unstructured":"Thi\u00e9baut, A., Thomas, X., Belhabri, A., Anglaret, B. & Archimbaud, E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann. Hematol. 79, 501\u2013506. https:\/\/doi.org\/10.1007\/s002770000162 (2000).","journal-title":"Ann. Hematol."},{"key":"85918_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan, A. et al. Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J. Clin. Apher. 34, 171\u2013354. https:\/\/doi.org\/10.1002\/jca.21705 (2019).","journal-title":"J. Clin. Apher."},{"key":"85918_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.transci.2018.02.006","volume":"57","author":"S Korkmaz","year":"2018","unstructured":"Korkmaz, S. The management of hyperleukocytosis in 2017: do we still need leukapheresis?. Transfus. Apher. Sci. 57, 4\u20137. https:\/\/doi.org\/10.1016\/j.transci.2018.02.006 (2018).","journal-title":"Transfus. Apher. Sci."},{"key":"85918_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544 (2016).","journal-title":"Blood"},{"key":"85918_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0002-9343(80)90467-2","volume":"69","author":"J Cuttner","year":"1980","unstructured":"Cuttner, J. et al. Association of monocytic leukemia in patients with extreme leukocytosis. Am. J. Med. 69, 555\u2013558. https:\/\/doi.org\/10.1016\/0002-9343(80)90467-2 (1980).","journal-title":"Am. J. Med."},{"key":"85918_CR16","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1002\/1097-0142(19871215)60:12<3071::aid-cncr2820601235>3.0.co;2-y","volume":"60","author":"U Creutzig","year":"1987","unstructured":"Creutzig, U., Ritter, J., Budde, M., Sutor, A. & Schellong, G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 60, 3071\u20133079. https:\/\/doi.org\/10.1002\/1097-0142(19871215)60:12%3c3071::aid-cncr2820601235%3e3.0.co;2-y (1987).","journal-title":"Cancer"},{"key":"85918_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1055\/s-2007-976170","volume":"33","author":"W Blum","year":"2007","unstructured":"Blum, W. & Porcu, P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin. Thromb. Hemost. 33, 350\u2013354. https:\/\/doi.org\/10.1055\/s-2007-976170 (2007).","journal-title":"Semin. Thromb. Hemost."},{"key":"85918_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/cncr.23581","volume":"113","author":"H Inaba","year":"2008","unstructured":"Inaba, H. et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer 113, 522\u2013529. https:\/\/doi.org\/10.1002\/cncr.23581 (2008).","journal-title":"Cancer"},{"key":"85918_CR19","doi-asserted-by":"publisher","first-page":"e95062","DOI":"10.1371\/journal.pone.0095062","volume":"9","author":"F Pastore","year":"2014","unstructured":"Pastore, F., Pastore, A., Wittmann, G., Hiddemann, W. & Spiekermann, K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS ONE 9, e95062\u2013e95062. https:\/\/doi.org\/10.1371\/journal.pone.0095062 (2014).","journal-title":"PLoS ONE"},{"key":"85918_CR20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood-2019-131998","volume":"134","author":"G Montalban Bravo","year":"2019","unstructured":"Montalban Bravo, G. et al. Outcomes of patients with acute myeloid leukemia (AML) with myelodysplasia related changes (AML-MRC) are dependent on diagnostic criteria and therapy. Blood 134, 1312\u20131312. https:\/\/doi.org\/10.1182\/blood-2019-131998 (2019).","journal-title":"Blood"},{"key":"85918_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.1.6121.1169","volume":"1","author":"AL Harris","year":"1978","unstructured":"Harris, A. L. Leukostasis associated with blood transfusion in acute myeloid leukaemia. Br. Med. J. 1, 1169\u20131171. https:\/\/doi.org\/10.1136\/bmj.1.6121.1169 (1978).","journal-title":"Br. Med. J."},{"key":"85918_CR22","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1080\/10428194.2018.1452219","volume":"59","author":"M Stahl","year":"2018","unstructured":"Stahl, M. et al. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey(). Leuk. Lymphoma 59, 2723\u20132726. https:\/\/doi.org\/10.1080\/10428194.2018.1452219 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"85918_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/10428190109097677","volume":"42","author":"FJ Giles","year":"2001","unstructured":"Giles, F. J. et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival. Leuk. Lymphoma 42, 67\u201373. https:\/\/doi.org\/10.3109\/10428190109097677 (2001).","journal-title":"Leuk. Lymphoma"},{"key":"85918_CR24","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/j.1537-2995.2007.01406.x","volume":"47","author":"G Bug","year":"2007","unstructured":"Bug, G. et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion 47, 1843\u20131850. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01406.x (2007).","journal-title":"Transfusion"},{"key":"85918_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ajh.20939","volume":"82","author":"M-C Chang","year":"2007","unstructured":"Chang, M.-C. et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am. J. Hematol. 82, 976\u2013980. https:\/\/doi.org\/10.1002\/ajh.20939 (2007).","journal-title":"Am. J. Hematol."},{"key":"85918_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.transci.2017.11.002","volume":"56","author":"UY Malkan","year":"2017","unstructured":"Malkan, U. Y. & Ozcebe, O. I. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis. Transfus. Apher. Sci. 56, 880\u2013882. https:\/\/doi.org\/10.1016\/j.transci.2017.11.002 (2017).","journal-title":"Transfus. Apher. Sci."},{"key":"85918_CR27","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood.V108.11.2007.2007","volume":"108","author":"KHM Kuo","year":"2006","unstructured":"Kuo, K. H. M. et al. Management of hyperleukocytosis in acute myelogenous leukemia using hydroxyurea rather than leukopheresis. Blood 108, 2007\u20132007. https:\/\/doi.org\/10.1182\/blood.V108.11.2007.2007 (2006).","journal-title":"Blood"},{"key":"85918_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.leukres.2014.01.004","volume":"38","author":"S Oberoi","year":"2014","unstructured":"Oberoi, S. et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk. Res. 38, 460\u2013468. https:\/\/doi.org\/10.1016\/j.leukres.2014.01.004 (2014).","journal-title":"Leuk. Res."},{"key":"85918_CR29","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1080\/10428194.2016.1277386","volume":"58","author":"X Nan","year":"2017","unstructured":"Nan, X. et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis\u2014a retrospective study from a tertiary center. Leuk. Lymphoma 58, 2110\u20132117. https:\/\/doi.org\/10.1080\/10428194.2016.1277386 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"85918_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0783-3","author":"M Stahl","year":"2020","unstructured":"Stahl, M. et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia https:\/\/doi.org\/10.1038\/s41375-020-0783-3 (2020).","journal-title":"Leukemia"},{"key":"85918_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/trf.14329","volume":"58","author":"MH Choi","year":"2018","unstructured":"Choi, M. H. et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion 58, 208\u2013216. https:\/\/doi.org\/10.1111\/trf.14329 (2018).","journal-title":"Transfusion"},{"key":"85918_CR32","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","volume":"98","author":"D Grimwade","year":"2001","unstructured":"Grimwade, D. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312\u20131320. https:\/\/doi.org\/10.1182\/blood.V98.5.1312 (2001).","journal-title":"Blood"},{"key":"85918_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","volume":"108","author":"SS Farag","year":"2006","unstructured":"Farag, S. S. et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108, 63\u201373. https:\/\/doi.org\/10.1182\/blood-2005-11-4354 (2006).","journal-title":"Blood"},{"key":"85918_CR34","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","volume":"108","author":"S Fro\u0308hling","year":"2006","unstructured":"Fro\u0308hling, S. et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108, 3280\u20133288. https:\/\/doi.org\/10.1182\/blood-2006-04-014324 (2006).","journal-title":"Blood"},{"key":"85918_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-019-0612-y","volume":"20","author":"Y Daneshbod","year":"2019","unstructured":"Daneshbod, Y., Kohan, L., Taghadosi, V., Weinberg, O. K. & Arber, D. A. Prognostic significance of complex karyotypes in acute myeloid leukemia. Curr. Treat. Options Oncol. 20, 15. https:\/\/doi.org\/10.1007\/s11864-019-0612-y (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"85918_CR36","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/cncr.28950","volume":"120","author":"C Motll\u00f3","year":"2014","unstructured":"Motll\u00f3, C. et al. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer 120, 3958\u20133964. https:\/\/doi.org\/10.1002\/cncr.28950 (2014).","journal-title":"Cancer"},{"key":"85918_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196 (2017).","journal-title":"Blood"},{"key":"85918_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jfma.2014.01.006","volume":"113","author":"KH Chen","year":"2014","unstructured":"Chen, K. H. et al. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. J. Formos. Med. Assoc. Taiwan yi zhi 113, 833\u2013838. https:\/\/doi.org\/10.1016\/j.jfma.2014.01.006 (2014).","journal-title":"J. Formos. Med. Assoc. Taiwan yi zhi"},{"key":"85918_CR39","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/trf.15994","volume":"60","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf, J. P., Giri, S., Tallman, M. S., Zeidan, A. M. & Stahl, M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia\u2014a systematic review and meta-analysis. Transfusion 60, 2360\u20132369. https:\/\/doi.org\/10.1111\/trf.15994 (2020).","journal-title":"Transfusion"},{"key":"85918_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1537-2995.1999.39199116894.x","volume":"39","author":"F Ravagnani","year":"1999","unstructured":"Ravagnani, F. et al. Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. Transfusion 39, 48\u201355. https:\/\/doi.org\/10.1046\/j.1537-2995.1999.39199116894.x (1999).","journal-title":"Transfusion"},{"key":"85918_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1537-2995.2000.40030368.x","volume":"40","author":"A Humpe","year":"2000","unstructured":"Humpe, A., Riggert, J., Munzel, U. & K\u00f6hler, M. A prospective, randomized, sequential crossover trial oflarge-volume versus normal-volume leukapheresis procedures:effects on serum electrolytes, platelet counts, and other coagulation measures. Transfusion 40, 368\u2013374. https:\/\/doi.org\/10.1046\/j.1537-2995.2000.40030368.x (2000).","journal-title":"Transfusion"},{"key":"85918_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.transci.2016.12.001","volume":"56","author":"A Van de Louw","year":"2017","unstructured":"Van de Louw, A. Effect of leukapheresis on blood coagulation in patients with hyperleukocytic acute myeloid leukemia. Transfus. Apher. Sci. 56, 214\u2013219. https:\/\/doi.org\/10.1016\/j.transci.2016.12.001 (2017).","journal-title":"Transfus. Apher. Sci."},{"key":"85918_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7326\/M14-1589","volume":"162","author":"RM Kaufman","year":"2015","unstructured":"Kaufman, R. M. et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann. Intern. Med. 162, 205\u2013213. https:\/\/doi.org\/10.7326\/M14-1589 (2015).","journal-title":"Ann. Intern. Med."},{"key":"85918_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.14423","volume":"176","author":"LJ Estcourt","year":"2017","unstructured":"Estcourt, L. J. et al. Guidelines for the use of platelet transfusions. Br. J. Haematol. 176, 365\u2013394. https:\/\/doi.org\/10.1111\/bjh.14423 (2017).","journal-title":"Br. J. Haematol."},{"key":"85918_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","volume":"122","author":"M Koupenova","year":"2018","unstructured":"Koupenova, M., Clancy, L., Corkrey, H. A. & Freedman, J. E. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ. Res. 122, 337\u2013351. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310795 (2018).","journal-title":"Circ. Res."},{"key":"85918_CR46","first-page":"65","volume":"16","author":"RA Ali","year":"2015","unstructured":"Ali, R. A., Wuescher, L. M. & Worth, R. G. Platelets: essential components of the immune system. Curr. Trends Immunol. 16, 65\u201378 (2015).","journal-title":"Curr. Trends Immunol."},{"key":"85918_CR47","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2019.01731","volume":"10","author":"M Mezger","year":"2019","unstructured":"Mezger, M. et al. Platelets and immune responses during thromboinflammation. Front. Immunol. 10, 1731\u20131731. https:\/\/doi.org\/10.3389\/fimmu.2019.01731 (2019).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85918-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:22:48Z","timestamp":1670026968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85918-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85918"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85918-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6426"}}